Provectus Announces Preliminary Results from Phase 1 Trial of PV-10 for Treatment of Metastatic Neuroendocrine Tumors at ASCO 2019
03 juin 2019 09h05 HE
|
Provectus Biopharmaceuticals Inc.
No safety concerns identified50% ORR and 83% disease control of injected lesionsStable Chromogranin A responses and quality of life scores for nearly all subjects KNOXVILLE, TN, June 03, 2019 ...
PROVECTUS ANNOUNCES PRESENTATION OF PHASE 1 TRIAL OF PV-10 FOR TREATMENT OF SYMPTOMATIC NEUROENDOCRINE TUMORS METASTATIC TO LIVER AT ESMO 2018 CONGRESS
23 oct. 2018 09h00 HE
|
Provectus Biopharmaceuticals Inc.
- First cohort of 6 patients enrolled and treated; currently recruiting patients into second cohort KNOXVILLE, TN, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that...